Jupiter Life Line Hospitals board approves 1:5 stock split, interim dividend; check key Q4 numbers

Its board of directors considered and approved the sub-division or split of one existing equity share of the company, with a face value of ₹10 each, fully paid-up, into five equity shares, with a face value of ₹2 each, fully paid-up, according to a regulatory filing dated May 15.

Interim dividend

Jupiter Life Line’s board of directors also considered and approved an interim dividend at the rate of 10% per equity share, with a face value of ₹10 each for FY26.

Furthermore, it fixed Friday, May 22, 2026, as the record date for the same.

“The dividend shall be paid on or before June 13, 2026, to those members whose names appear on the Register of Members or in records of Depositories as beneficial owners as on the Record Date,” the filing read.

Jupiter Life Line Q4 results

The company reported a 15.04% year-on-year (YoY) surge in its consolidated net profit to ₹50.62 crore in the fourth quarter of FY26 (Q4 FY26), compared to ₹44 crore in the same period last year.

Its revenue from operations jumped 15.2% YoY to ₹387.84 crore during the quarter under review, as against ₹336.66 crore in the March quarter of the 2024-25 fiscal year (Q4 FY25).

At an operational level, its EBITDA (earnings before interest, tax, depreciation, and amortisation), also known as operating profit, stood at ₹89.2 crore in Q4 FY26, up 12.3% YoY from ₹79.4 crore in the year-ago period.

Its EBITDA margin contracted to 23% in the reporting quarter, in comparison to 23.6% in Q4 FY25.

Jupiter Life Line’s EBITDA includes an operational loss of ₹9.4 crore from its Dombivli Hospital during the initial ramp-up phase. Furthermore, the commercialisation of Dombivli hospital increased depreciation expense.

Its finance costs increased YoY owing to an increase in gross debt levels undertaken to fund ongoing capital expenditure, the firm stated.

What the CEO said

Commenting on its performance for FY26, Dr. Ankit Thakker, Joint Managing Director (JMD) and the Chief Executive Officer (CEO), said: “FY26 has been a landmark year for us, marked by two significant milestones, the acquisition of land at BKC for setting up a 400-bed hospital and operationalization of Dombivli hospital on 25th February 2026. The project was delivered on budget and before time, ahead of its scheduled launch date of Q1 FY27.”

With these, he added that Jupiter Life Line will have four hospitals in the Mumbai Metropolitan Region (MMR), two in Pune and one in Indore, further cementing its “leadership position in Western India”.

However, Dr. Thakker stated that the ahead-of-schedule implementation of the Dombivali hospital meant that its Q4 earnings were impacted by the drag on its opex losses and the depreciation on account of its capitalisation.

“I am pleased to report that the Thane, Pune, and Indore hospitals are performing on expected lines, and the Pune South construction is progressing on schedule,” Dr. Thakker further said.

Jupiter Life Line Hospitals stock performance

Shares of Jupiter Life Line Hospitals declined as much as 2.86% to hit an intraday low of ₹1,288.60 apiece on the National Stock Exchange (NSE) on Monday, May 18.

At around 11:06 AM, it was trading 1.93% lower at ₹1,335 per equity share.

The scrip has gained 3% in the past week and 1% over the month. However, on a year-to-date basis, it has fallen 7%.

While the stock hit a 52-week high of ₹1,625 on October 30, 2025, it touched a year’s low of ₹1,178 per unit on April 6, 2026,

Jupiter Life Line Hospitals has a total market capitalisation of ₹8,753.06 crore as of May 18, 2026, according to data on the NSE.